EVH (Evolent Health) Long-Term Debt: $973 Mil (As of Mar. 2026)


EVH Evolent Health Inc EVH
62 GF Score
Price $5.48
GF Value $11.21
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Evolent Health Long-Term Debt?

Evolent Health EVH -4.53% 62 Long-Term Debt is $973 Mil as of Mar. 2026. GuruFocus rates EVH with a GF Score™ of 62/100 and a GF Value™ of $11.21 (Possible Value Trap). The stock has 7 warning signs investors should review.

Evolent Health's Long-Term Debt for the quarter that ended in Mar. 2026 was $973 Mil.

Evolent Health's quarterly Long-Term Debt declined from Sep. 2025 ($1,055 Mil) to Dec. 2025 ($971 Mil) but then increased from Dec. 2025 ($971 Mil) to Mar. 2026 ($973 Mil).

Evolent Health's annual Long-Term Debt declined from Dec. 2023 ($597 Mil) to Dec. 2024 ($491 Mil) but then increased from Dec. 2024 ($491 Mil) to Dec. 2025 ($971 Mil).

Evolent Health  (NYSE:EVH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Evolent Health Long-Term Debt Related Terms

Evolent Health Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Evolent Health's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolent Health Long-Term Debt Chart

Evolent Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 215.68 412.99 597.05 490.52 970.54

Evolent Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 647.53 648.46 1,054.82 970.54 973.49
EVH
62GF Score
Evolent Health Inc EVH
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $973 Mil mean?
Evolent Health (EVH) has a Long-Term Debt of $973 Mil as of Mar. 2026.
Is Evolent Health's Long-Term Debt too high?
Evolent Health's current Long-Term Debt is $973 Mil. Overall, Evolent Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's Long-Term Debt compare to PHR and CTEV?
Evolent Health's Long-Term Debt of $973 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Healthcare Providers & Services company?
A good Long-Term Debt depends on the Healthcare Providers & Services industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Evolent Health's current Long-Term Debt is $973 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (EVH) is currently considered Possible Value Trap. The stock's GF Value™ is $11.21, compared to a current price of $5.48 — trading 51.1% below its estimated fair value. The current Long-Term Debt is $973 Mil. Evolent Health's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Evolent Health (EVH), the current Long-Term Debt is $973 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolent Health (EVH) Overvalued in 2026?

Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued. The current stock price of $5.48 is trading 51.1% below its estimated GF Value™ of $11.21. GuruFocus considers Evolent Health to be Possible Value Trap.

Key valuation signals for EVH:

  • Long-Term Debt: $973 Mil
  • GF Value™: $11.21 vs. price of $5.48 (51.1% below fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the EVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evolent Health Business Description

Other Exchanges 9EH:Germany
Address 1812 North Moore Street, Suite 1705, Arlington, VA, USA, 22209
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
62GF Score

Get the complete analysis for EVH

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.48
Price
$11.21
GF Value